Physician profile
Victor S Evans
NPI 1386703700
$25,858.15
in general payments reported to CMS, 2019-2025
16 companies · $579 in 2025
The $579 reported for 2025 was more than what 78% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,243 · 2021: $3,392 · 2022: $619 · 2023: $2,849 · 2024: $436 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,680 · Consulting Fee: $360 · Travel and Lodging: $6.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,680.00 |
| Consulting Fee | $360.00 |
| Travel and Lodging | $6.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15,059.64 | 2019-2025 | Trintellix |
| Tris Pharma INC | $6,454.61 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $2,524.98 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $645.12 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $360.98 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $175.64 | 2019-2024 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $128.86 | 2019 | |
| Neos Therapeutics, LP | $108.19 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Adlon Therapeutics L.P. | $91.69 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $65.92 | 2019-2020 | |
| Noven Therapeutics, LLC | $65.76 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $54.13 | 2025 | Jornay Pm |
| Shire North American Group INC | $44.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $34.07 | 2021-2025 | Rexulti |
| Lundbeck LLC | $29.80 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.